wildpixel
- Immuneering Corp. (IMRX) is down ~21% in after-hours trading Wednesday after posting phase 2a results on atebimetinib as a first-line treatment for pancreatic cancer.
- The biotech reported 64% overall survival at 12 months in patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP). The